On September 20, 2023, it was announced that DnB Asset Management AS has acquired a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the second quarter. The firm purchased 10,902 shares of the company’s stock, with an estimated value of around $358,000.
Ventyx Biosciences recently disclosed its earnings results on August 10th. Unfortunately, the company reported earnings per share (EPS) of ($0.91) for the quarter, which fell short of analysts’ consensus estimates by ($0.20). In comparison to the same quarter in the previous year when they earned ($0.39) per share, this indicates a decline in performance. A group of sell-side analysts predicts that Ventyx Biosciences will report earnings per share of -3.26 for the current fiscal year.
In other news surrounding Ventyx Biosciences, insider John Nuss sold 20,000 shares of the company’s stock on July 3rd at an average price of $39.58 per share. The total transaction amounted to $791,600. Following this sale, Nuss now directly holds 244,815 shares in Ventyx Biosciences valued at approximately $9,689,777.70. The transaction was duly disclosed in a legal filing with the Securities & Exchange Commission [SEC].
Moreover, there is another disclosure regarding insider John Nuss’s sale of 20,000 shares on July 3rd at an average price of $39.58 per share amounting to a total transaction value of $791,600. Following this sale as well, Nuss owns 244,815 shares worth around $9,689,777.70 in the company This particular filing is also accessible through a hyperlink provided by the Securities & Exchange Commission.
Furthermore., insider William J. Sandborn also made a transaction by selling 11,900 shares of Ventyx Biosciences stock on August 31st at an average price of $33.64 per share. The total value of the transaction stood at $400,316. Following this sale, Sandborn now holds 48,389 shares in the company valued at about $1,627,805.96. Details of this sale can be obtained from the disclosure.
Over the past ninety days, insiders have sold a significant amount of company stock with a cumulative value of $15,989,298. Ultimately, corporate insiders own 24.39% of Ventyx Biosciences’ stock.
References:
1. Securities and Exchange Commission: [link to be included]
2. Disclosure for insider transactions: [link to be included]
[bs_slider_forecast ticker=”CRUS”]
Strong Institutional Interest Drives Confidence in Ventyx Biosciences
September 20, 2023
Ventyx Biosciences Garners Interest from Institutional Investors
In recent months, Ventyx Biosciences has caught the attention of several hedge funds and institutional investors, leading to significant changes in their positions within the company. One notable investor, FMR LLC, increased its holdings in Ventyx Biosciences by an astonishing 348.8% during the first quarter of this year. The firm now owns a massive 7,604,341 shares valued at $254,745,000.
Price T Rowe Associates Inc. MD also demonstrated optimism towards Ventyx Biosciences by growing its holdings by 48.7% during the same period. Similarly, BlackRock Inc. expanded its ownership by 4.0%. Meanwhile, Avidity Partners Management LP acquired a new stake in Ventyx Biosciences during the fourth quarter.
This surge in interest from institutional investors indicates a strong belief in the potential of Ventyx Biosciences within the bioscience industry. These investments demonstrate confidence in the company’s future growth prospects and its ability to deliver significant returns for its shareholders.
Vanguard Group Inc., a reputable investment management company, also recently reported growing their holdings in Ventyx Biosciences by 21.7% during the third quarter of last year. Their increased stake now amounts to 1,103,953 shares valued at $38,539,000.
The positive sentiments surrounding Ventyx Biosciences have not gone unnoticed by analysts either. In various reports issued recently, analysts have consistently expressed optimism about the company’s potential for success.
Credit Suisse Group lowered their price target on Ventyx Biosciences but maintained an “outperform” rating on the stock in their research report released on August 11th. Morgan Stanley raised their price objective on Ventyx Biosciences and assigned an “overweight” rating, indicating confidence in the stock’s performance. Additionally, Oppenheimer and HC Wainwright dropped their price targets on Ventyx Biosciences but maintained positive outlooks.
The consensus among seven investment analysts is that Ventyx Biosciences is a promising investment opportunity, with all of them giving it a buy rating. These ratings are in line with the average target price of $57.88, as reported by Bloomberg.com.
As of September 20, 2023, VTYX shares opened at $37.58 on the NASDAQ exchange. The stock has demonstrated stability, with a 50-day simple moving average of $34.17 and a 200-day simple moving average of $34.95.
Ventyx Biosciences’ market capitalization currently stands at an impressive $2.21 billion, an indication of investors’ confidence in the company’s future growth prospects. With a PE ratio of -13.42 and a beta of -0.36, VTYX presents itself as an intriguing option for those seeking to invest in the bioscience sector.
In conclusion, the recent surge in interest from hedge funds and institutional investors highlights the growing confidence in Ventyx Biosciences’ potential for success within the industry. Coupled with positive analyst reports and favorable target prices, these developments position VTYX as an attractive investment opportunity for those seeking potential upside in their portfolio.
